Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

This study is testing the cancer drug sacituzumab govitecan (an antibody-drug combination that targets cancer cells) in people with advanced or metastatic solid tumors who also have moderate liver impairment. The goal is to understand how the drug behaves and what doses are safe when the liver is not functioning normally. **You may be eligible if...** - You have a confirmed advanced or metastatic solid tumor - You are in reasonably good health overall (ECOG 0–2) - Your blood counts are adequate without recent transfusions - Your kidney function is at least minimally adequate - You either have normal liver function OR have moderate liver impairment **You may NOT be eligible if...** - You have severe liver impairment - Your blood counts, kidney function, or overall health are too poor - You are pregnant or breastfeeding - You have had severe prior reactions to similar drugs (irinotecan-based therapies) Talk to your doctor to see if this trial is right for you.